3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a staple holding in many investors' portfolios. Its superior 2.5% dividend yield and 55-year streak of raising its payout has attracted a cadre of income investors, while an array of value, income, and growth investors have bought into the Johnson & Johnson thesis on the basis of its operational diversity.
J&J, as it's more commonly known, is comprised of three operating segments, each of which serves a purpose. Pharmaceuticals, which is J&J's largest segment by revenue generation, provides rapid growth and high margins. Meanwhile, medical devices provides a long-tail growth opportunity amid an aging global population, and consumer health products delivers strong pricing power and predictable cash flow.
Image source: Getty Images.
Source: Fool.com